source
- GSK terminates $700 million Alector partnership after recent trial setbacksGSK has decided to end its collaboration with Alector, a biotech focused on neurodegenerative diseases. The agreement originally included a $700 million upfront payment. The move follows two high-…
- Roche scraps two Ionis-partnered Huntington’s drugsThe Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of a second drug was scrapped because of a safety signal in animal testing.